HEALTHCARE PROFESSIONAL RESOURCES
This resource section is designed to provide you with helpful information about respiratory distress syndrome in premature infants and CUROSURF. Find clinical resources and videos all in one convenient place.
WANT TO BE CONTACTED BY A CHIESI SALES REPRESENTATIVE?
VISIT OFFICIAL CUROSURF YOUTUBE CHANNEL
CUROSURF User Guide Video
The User Guide Video details the safety and efficacy data behind CUROSURF, and walks through the storage, dosing, and administration procedures found in our Full Prescribing Information. This video may be particularly helpful during a Skills Day or for educating new staff.
INSURE: An Option for Treating Infants Following NIV Failure
This short video provides an overview of some of the research behind the INSURE strategy and a detailed step-by-step video guide of how to administer CUROSURF.
Evaluating Surfactants for Formulary
Since surfactants cannot be considered pharmaceutical equivalents, it is important to evaluate the drug class comprehensively. This white paper discusses some factors to consider and which stakeholders to consult as you evaluate the surfactant class.
We worked with Carla Christensen, PharmD, to develop this video presentation of some of the considerations that she recommends incorporating into a surfactant Medication Use Evaluation.
The INSURE Strategy: Selective Surfactant Following nCPAP Failure
In this lecture, Dana Evans, MHA, RRT-NPS, highlights some of the latest research into less invasive ventilation for babies with respiratory distress syndrome, and how CUROSURF may be a good fit for your protocols.
A Comparison of Approved Natural Surfactants
In this “grand rounds style” lecture, Lance Parton, MD, FAAP, presents some of the similarities and differences between the currently available natural exogenous surfactants.
Evaluating Surfactants: A Pharmacy Perspective
Presented by Jennifer Gorrell, PharmD, this “grand rounds style” presentation includes some information about surfactants that might be helpful to consider from a pharmacy perspective.
Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.
It is important to note that the INSURE strategy may not be appropriate for all infants. Infants with RDS may vary markedly in the severity of respiratory disease, maturity, and presence of other complications, and thus it is necessary to individualize patient care.